Implicit Bioscience
Home Company People Technology Strategy Contact
Leveraging products and finance to reduce risk and improve outcomes for patients and shareholders.

 

Our focus is on diseases which are modulated by the host immune response. We use a virtual biotech model to identify clinical-stage assets for high-value development which is designed to unlock major benefits for both patients and shareholders. Where possible, we leverage our investor capital with non-dilutive funding by directing our effort at disease targets with high national strategic value.

 

IMPLICIT AND CMC ICOS ANNOUNCE IC14 MANUFACTURING AGREEMENT AND PATENT LICENSE

8 May 2009

Implicit Bioscience Ltd and CMC ICOS Biologics today announced the execution of a manufacturing contract to support the next stage of development and commercialization of IC14, a clinical-stage monoclonal antibody for acute lung injury (ALI). ...(click here to read more)

Privacy Policy     |     Legal Notice